{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:56:39Z","timestamp":1791338199666,"version":"4.3.1"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Virology"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.coviro.2014.07.006","type":"journal-article","created":{"date-parts":[[2014,8,14]],"date-time":"2014-08-14T13:25:46Z","timestamp":1408022746000},"page":"98-103","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Resistance to HIV integrase strand transfer inhibitors: in vitro findings and clinical consequences"],"prefix":"10.1016","volume":"8","author":[{"given":"Jay A.","family":"Grobler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria J.","family":"Hazuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coviro.2014.07.006_bib0005","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0140-6736(08)61113-7","article-title":"Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies","volume":"372","author":"The Antiretroviral Therapy Cohort Collaboration","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.coviro.2014.07.006_bib0010","doi-asserted-by":"crossref","first-page":"e81355","DOI":"10.1371\/journal.pone.0081355","article-title":"Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada","volume":"8","author":"Samji","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.coviro.2014.07.006_bib0015","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/rmv.624","article-title":"The history of antiretrovirals: key discoveries over the past 25 years","volume":"19","author":"De Clercq","year":"2009","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.coviro.2014.07.006_bib0020","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1517\/14656566.2014.863277","article-title":"Emerging antiretroviral drugs","volume":"15","author":"Fernandez-Montero","year":"2014","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.coviro.2014.07.006_bib0025","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1086\/430005","article-title":"Estimating HIV evolutionary pathways and the genetic barrier to drug resistance","volume":"191","author":"Beerenwinkel","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2014.07.006_bib0030","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3109\/07853890.2014.883169","article-title":"Integrase strand transfer inhibitors in the management of HIV-positive individuals","volume":"46","author":"Mesplede","year":"2014","journal-title":"Ann Med"},{"key":"10.1016\/j.coviro.2014.07.006_bib0035","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1097\/QCO.0b013e32835a1de7","article-title":"Emerging patterns and implications of HIV-1 integrase inhibitor resistance","volume":"25","author":"Geretti","year":"2012","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.coviro.2014.07.006_bib0040","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.antiviral.2013.01.007","article-title":"Molecular basis of human immunodeficiency virus type 1 drug resistance: overview and recent developments","volume":"98","author":"Menendez-Arias","year":"2013","journal-title":"Antiviral Res"},{"key":"10.1016\/j.coviro.2014.07.006_bib0045","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/QCO.0b013e32835ba81c","article-title":"Evolution of HIV integrase resistance mutations","volume":"26","author":"Quashie","year":"2013","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.coviro.2014.07.006_bib0050","doi-asserted-by":"crossref","first-page":"6661","DOI":"10.1073\/pnas.092056199","article-title":"Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes","volume":"99","author":"Grobler","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2014.07.006_sbref0055","doi-asserted-by":"crossref","first-page":"20057","DOI":"10.1073\/pnas.1010246107","article-title":"Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance","volume":"107","author":"Hare","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2014.07.006_bib0060","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1093\/infdis\/jir636","article-title":"Cross-resistance profile of the novel integrase inhibitor Dolutegravir (S\/GSK1349572) using clonal viral variants selected in patients failing raltegravir","volume":"204","author":"Canducci","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2014.07.006_bib0065","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1128\/AAC.01209-10","article-title":"In vitro antiretroviral properties of S\/GSK1349572, a next-generation HIV integrase inhibitor","volume":"55","author":"Kobayashi","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coviro.2014.07.006_bib0070","doi-asserted-by":"crossref","first-page":"9210","DOI":"10.1128\/JVI.01164-10","article-title":"Identification of novel mutations responsible for resistance to MK-2048, a second-generation HIV-1 integrase inhibitor","volume":"84","author":"Bar-Magen","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2014.07.006_sbref0075","doi-asserted-by":"crossref","DOI":"10.1093\/jac\/dku095","article-title":"New raltegravir resistance pathways induce broad cross-resistance to all currently used integrase inhibitors","author":"Malet","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.coviro.2014.07.006_bib0080","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1128\/JVI.06591-11","article-title":"Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir","volume":"86","author":"Quashie","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2014.07.006_bib0085","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1742-4690-11-7","article-title":"The M50I polymorphic substitution in association with the R263K mutation in HIV-1 subtype B integrase increases drug resistance but does not restore viral replicative fitness","volume":"11","author":"Wares","year":"2014","journal-title":"Retrovirology"},{"key":"10.1016\/j.coviro.2014.07.006_bib0090","doi-asserted-by":"crossref","first-page":"11233","DOI":"10.1073\/pnas.0402357101","article-title":"A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase","volume":"101","author":"Hazuda","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2014.07.006_sbref0095","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(12)61853-4","article-title":"Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study","volume":"381","author":"Raffi","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.coviro.2014.07.006_sbref0100","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/S0140-6736(14)60084-2","article-title":"Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study","volume":"383","author":"Clotet","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.coviro.2014.07.006_sbref0105","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1097\/QAI.0000000000000089","article-title":"A randomized, double-blind comparison of single-tablet regimen elvitegravir\/cobicistat\/emtricitabine\/tenofovir DF vs ritonavir-boosted atazanavir plus emtricitabine\/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results","volume":"65","author":"Clumeck","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.coviro.2014.07.006_bib0110","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1016\/S0140-6736(12)60918-0","volume":"379","author":"DeJesus","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.coviro.2014.07.006_bib0115","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S0140-6736(09)60918-1","article-title":"Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial","volume":"374","author":"Lennox","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.coviro.2014.07.006_sbref0120","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/QAI.0b013e31828ace69","article-title":"Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir\/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK","volume":"63","author":"Rockstroh","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.coviro.2014.07.006_bib0125","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1016\/S0140-6736(12)60917-9","article-title":"Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks","volume":"379","author":"Sax","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.coviro.2014.07.006_bib0130","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1056\/NEJMoa1215541","article-title":"Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection","volume":"369","author":"Walmsley","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2014.07.006_bib0135","doi-asserted-by":"crossref","first-page":"e118","DOI":"10.1097\/QAI.0000000000000057","article-title":"A randomized, double-blind comparison of single-tablet regimen elvitegravir\/cobicistat\/emtricitabine\/tenofovir DF versus single-tablet regimen efavirenz\/emtricitabine\/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results","volume":"65","author":"Wohl","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.coviro.2014.07.006_bib0140","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S0140-6736(13)61221-0","article-title":"Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study","volume":"382","author":"Cahn","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.coviro.2014.07.006_bib0145","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ijantimicag.2013.10.013","article-title":"Four years data of raltegravir-based salvage therapy in HIV-1-infected, treatment-experienced patients: the SALIR-E study","volume":"43","author":"Capetti","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.coviro.2014.07.006_bib0150","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/QAI.0b013e318298469c","article-title":"A randomized phase 3 study comparing once-daily elvitegravir with twice-daily raltegravir in treatment-experienced subjects with HIV-1 infection: 96-week results","volume":"63","author":"Elion","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.coviro.2014.07.006_bib0155","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S1473-3099(13)70093-8","article-title":"Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials","volume":"13","author":"Eron","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.coviro.2014.07.006_bib0160","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1473-3099(11)70249-3","article-title":"Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study","volume":"12","author":"Molina","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.coviro.2014.07.006_bib0165","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiu051","article-title":"Dolutegravir in antiretroviral-experienced patients with raltegravir- and\/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study","author":"Castagna","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coviro.2014.07.006_bib0170","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.coviro.2012.08.006","article-title":"Are subtype differences important in HIV drug resistance?","volume":"2","author":"Lessells","year":"2012","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.coviro.2014.07.006_bib0175","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1097\/QAD.0b013e328348065a","article-title":"Clinical efficacy of raltegravir against B and non-B subtype HIV-1 in phase III clinical studies","volume":"25","author":"Rockstroh","year":"2011","journal-title":"AIDS"},{"key":"10.1016\/j.coviro.2014.07.006_bib0180","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1097\/QAD.0b013e32833cf265","article-title":"HIV-1 subtype B and C integrase enzymes exhibit differential patterns of resistance to integrase inhibitors in biochemical assays","volume":"24","author":"Bar-Magen","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.coviro.2014.07.006_bib0185","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1093\/jac\/dkp423","article-title":"Integrase variability and susceptibility to HIV integrase inhibitors: impact of subtypes, antiretroviral experience and duration of HIV infection","volume":"65","author":"Garrido","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.coviro.2014.07.006_bib0190","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.antiviral.2011.03.178","article-title":"Resistance associated mutations to dolutegravir (S\/GSK1349572) in HIV-infected patients\u2014impact of HIV subtypes and prior raltegravir experience","volume":"90","author":"Garrido","year":"2011","journal-title":"Antiviral Res"}],"container-title":["Current Opinion in Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625714001515?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625714001515?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T13:06:24Z","timestamp":1649941584000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879625714001515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":38,"alternative-id":["S1879625714001515"],"URL":"https:\/\/doi.org\/10.1016\/j.coviro.2014.07.006","relation":{},"ISSN":["1879-6257"],"issn-type":[{"value":"1879-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Resistance to HIV integrase strand transfer inhibitors: in vitro findings and clinical consequences","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coviro.2014.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}